Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.

Arthritis Rheumatol. 2016 Mar;68(3):761-8. doi: 10.1002/art.39466.

PMID:
26474155
2.

Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy.

Robinson AB, Tangpricha V, Yow E, Gurion R, Schanberg LE, McComsey GA; APPLE Investigators.

Lupus Sci Med. 2014 Sep 10;1(1):e000037. doi: 10.1136/lupus-2014-000037. eCollection 2014.

3.

Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy.

Robinson AB, Tangpricha V, Yow E, Gurion R, McComsey GA, Schanberg LE; APPLE Investigators.

Lupus Sci Med. 2014 Apr 30;1(1):e000011. doi: 10.1136/lupus-2014-000011. eCollection 2014.

4.

Medical students' experiences working with frequently rotating pediatric inpatient attending physicians.

Seltz LB, Montgomery A, Lane JL, Soep J, Hanson JL.

Hosp Pediatr. 2014 Jul;4(4):239-46. doi: 10.1542/hpeds.2014-0016.

5.

Pulmonary capillaritis in monozygotic twin boys.

Kupfer O, Ridall LA, Hoffman LM, Dishop MK, Soep JB, Wagener JS, Fan LL.

Pediatrics. 2013 Nov;132(5):e1445-8. doi: 10.1542/peds.2013-0154. Epub 2013 Oct 14.

6.

Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Wahezi DM, Ilowite NT, Wu XX, Pelkmans L, Laat B, Schanberg LE, Rand JH; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Lupus. 2013 Jun;22(7):702-11. doi: 10.1177/0961203313490241. Epub 2013 May 20.

7.

Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.

Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans GW, Yow E, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, Levy D, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy DK, Klein-Gitelman M, Wallace C, Silver RM, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Thompson SD; APPLE investigators.

Ann Rheum Dis. 2014 Mar;73(3):557-66. doi: 10.1136/annrheumdis-2012-202315. Epub 2013 Feb 22.

8.

Arteriopathy, D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic stroke.

Goldenberg NA, Jenkins S, Jack J, Armstrong-Wells J, Fenton LZ, Stence NV, Oleszek J, Boada R, Wilkening GN, Wilkinson C, Soep JB, Miyamoto SD, Bajaj L, Mourani PM, Manco-Johnson MJ, Bernard TJ.

J Pediatr. 2013 May;162(5):1041-6.e1. doi: 10.1016/j.jpeds.2012.11.035. Epub 2012 Dec 20.

9.

Treatment, survival, and thromboembolic outcomes of thrombotic storm in children.

Manco-Johnson MJ, Wang M, Goldenberg NA, Soep J, Gibson E, Knoll CM, Mourani PM.

J Pediatr. 2012 Oct;161(4):682-8.e1. doi: 10.1016/j.jpeds.2012.03.042. Epub 2012 May 11.

PMID:
22578585
10.

Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.

Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, Hsu J, Klein-Gitelman M, Moorthy LN, Muscal E, Radhakrishna SM, Wagner-Weiner L, Adams M, Blier P, Buckley L, Chalom E, Chédeville G, Eichenfield A, Fish N, Henrickson M, Hersh AO, Hollister R, Jones O, Jung L, Levy D, Lopez-Benitez J, McCurdy D, Miettunen PM, Quintero-del Rio AI, Rothman D, Rullo O, Ruth N, Schanberg LE, Silverman E, Singer NG, Soep J, Syed R, Vogler LB, Yalcindag A, Yildirim-Toruner C, Wallace CA, Brunner HI; Carra SLE Subcommittee.

Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83. doi: 10.1002/acr.21558.

11.

Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645.

12.

Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab.

Popler J, Alimohammadi M, Kämpe O, Dalin F, Dishop MK, Barker JM, Moriarty-Kelsey M, Soep JB, Deterding RR.

Pediatr Pulmonol. 2012 Jan;47(1):84-7. doi: 10.1002/ppul.21520. Epub 2011 Sep 7.

PMID:
21901851
13.

American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis.

Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation.

Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36. doi: 10.1002/acr.20497.

14.

Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children.

Takatsuki S, Soep JB, Calderbank M, Ivy DD.

Pediatr Cardiol. 2011 Aug;32(6):828-33. doi: 10.1007/s00246-011-9950-7. Epub 2011 Mar 30.

15.

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski Kl, Ilowite NT, von Scheven E, Eberhard A, Levy DM, Kimura Y, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung LK, Imundo L, Soep JB, Reed AM; APPLE investigators.

Lupus. 2010 Oct;19(11):1315-25. doi: 10.1177/0961203310373937.

16.

Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist.

Canna S, Frankovich J, Higgins G, Narkewicz MR, Nash SR, Hollister JR, Soep JB, Dragone LL.

Pediatr Rheumatol Online J. 2009 Dec 22;7:21. doi: 10.1186/1546-0096-7-21.

17.

Biomarkers of hypercoagulability and inflammation in childhood-onset arterial ischemic stroke.

Bernard TJ, Fenton LZ, Apkon SD, Boada R, Wilkening GN, Wilkinson CC, Soep JB, Miyamoto SD, Tripputi M, Armstrong-Wells J, Benke TA, Manco-Johnson MJ, Goldenberg NA.

J Pediatr. 2010 Apr;156(4):651-6. doi: 10.1016/j.jpeds.2009.10.034. Epub 2009 Dec 21.

PMID:
20022340
18.

Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Levy DM, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed A; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Arthritis Rheum. 2009 May;60(5):1496-507. doi: 10.1002/art.24469.

19.

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.

Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J.

J Clin Rheumatol. 2009 Jun;15(4):161-4. doi: 10.1097/RHU.0b013e3181a4f459.

PMID:
19363453
20.

Pernio in pediatrics.

Simon TD, Soep JB, Hollister JR.

Pediatrics. 2005 Sep;116(3):e472-5.

PMID:
16140694
Items per page

Supplemental Content

Loading ...
Write to the Help Desk